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Background: Patient-driven initiatives have made uptake of Do-it-Yourself Artificial Pancreas Systems (DIYAPS) increasingly
popular among people with diabetes of all ages. Observational studies have shown improvements in glycemic control and quality
of life among adults with diabetes. However, there is a lack of research examining outcomes of children and adolescents with
DIYAPS in everyday life and their social context.
Objective: This survey assesses the self-reported clinical outcomes of a pediatric population using DIYAPS in the real world.
Methods: An online survey was distributed to caregivers to assess the hemoglobin A1c levels and time in range (TIR) before
and after DIYAPS initiation and problems during DIYAPS use.
Results: A total of 209 caregivers of children from 21 countries responded to the survey. Of the children, 47.4% were female,
with a median age of 10 years, and 99.4% had type 1 diabetes, with a median duration of 4.3 years (SD 3.9). The median duration
of DIYAPS use was 7.5 (SD 10.0) months. Clinical outcomes improved significantly, including the hemoglobin A1c levels (from
6.91% [SD 0.88%] to 6.27% [SD 0.67]; P<.001) and TIR (from 64.2% [SD 15.94] to 80.68% [SD 9.26]; P<.001).
Conclusions: Improved glycemic outcomes were found across all pediatric age groups, including adolescents and very young
children. These findings are in line with clinical trial results from commercially developed closed-loop systems.
(JMIR Mhealth Uhealth 2019;7(7):e14087)  doi: 10.2196/14087
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Over 30 years ago, the Diabetes Control and Complications
Trial showed benefits of intensive diabetes management in
delaying the onset and reducing the severity of diabetes-related
complications [1]. People diagnosed at a young age are
particularly at risk for developing long-term complications and
comorbidities during childhood and later throughout life. Owing
to this, therapeutic guidelines recommend tight glycemic control,
with a target hemoglobin A1c (HbA1c) level<7.0% (53
mmol/mol) for all people with diabetes [2]. For children,
adolescents, and young adults, guidelines even recommend the
lowest achievable HbA1c without undue exposure to severe
hypoglycemia, balanced with quality of life and burden of care
[3]. Today, despite significant advances in therapy and
technological developments, only 17% of all children and
adolescents with diabetes achieve an HbA1c level<7.5% (58
mmol/mol) [4].
Multiple clinical trials have shown that closed-loop insulin
delivery systems (also known as automated insulin delivery
systems or “artificial pancreas”) designed for commercial use
are safe and effective in reducing hyper- and hypoglycemia in
people of all age groups with diabetes, including adolescents
and children [5-9]. Closed-loop systems are characterized by
automated insulin delivery in response to the user’s glucose
level. Although commercial systems are under development
and some have recently become available in a limited number
of countries, they are not universally available, accessible, or
affordable. Behind the hashtag #WeAreNotWaiting, a
community of people with diabetes and their families have
created new tools and systems, in addition to the existing,
already approved medical devices, and shared them via open
source platforms in order to help others with diabetes better
utilize their devices and data. One of the most significant
innovations to emerge through this movement is the
Do-it-Yourself Artificial Pancreas System (DIYAPS). In
DIYAPS, commercially available and approved medical devices
such as insulin pumps and continuous glucose monitoring
sensors are connected and remotely controlled by systems using
open-source algorithms to automate insulin delivery. While
these systems are cocreated by the DIYAPS community, each
user has to build his/her own system and use it at his/her own
risk. This includes children and adolescents whose caregivers
build and maintain these systems on their behalf.
Initial observational studies have shown significant
improvements in glycemic control, quality of life, and sleep
quality in adult DIYAPS users [10-12]. A Czech pilot study
was the first to report findings in a pediatric population and
showed that AndroidAPS (an Android-based DIYAPS) was a
safe and feasible alternative to a commercially available system,
with predictive low glucose suspension during a winter sports
camp [13]. There remains, however, a lack of research
examining outcomes of children and adolescents with DIYAPS
in everyday life and their social context. This survey assesses
the self-reported clinical outcomes of this specific user group.
Methods
An online survey was distributed to caregivers using DIYAPS
through the Facebook groups “Looped” (>11,500 members as
of May 2019) and “AndroidAPS users” (>2800 members as of
May 2019), other regional subgroups on Facebook, and Twitter.
In this context, a caregiver was either a family member or
another person who regularly looked after the child or adolescent
with diabetes. Demographics and socioeconomic status of the
study population were assessed. Participants were also asked
for their child’s last three HbA1c measurements and mean time
in range (TIR; sensor glucose level between 70 mg/dL or 4.0
mmol/L and 180 mg/dL or 10.0 mmol/L) before and after
DIYAPS commencement. In an open-ended question, we asked
respondents if they experienced difficulties in making the
transition to DIYAPS.
The survey was designed by an interdisciplinary team of medical
doctors, social scientists, public health researchers, and patient
innovators. Participants were able to choose between two
languages (English and German). Data were collected, managed,
and analyzed using the secure REDCap electronic data capture
tools hosted at Charité - Universitaetsmedizin Berlin [14].
Arithmetic mean, SD, and two-tailed heteroscedastic t test were
used to perform the statistical analysis. The survey was approved
by the Charité ethics committee (EA2/140/18).
Results
Overall, 209 participants from 21 countries (74.3% from Europe,
12.0% from North America, 6.9% from Asia, and 6.9% from
Australia) responded to the survey (Table 1). Of the total, 47.4%
children were female, with a median age of 10 years (range:
3-20 years), and 99.4% had type 1 diabetes. The median duration
of diabetes was 4.3 (SD 3.9) years, and various types of
DIYAPS (AndroidAPS, 48.0%; OpenAPS, 28.4%; Loop, 28.4%;
other, 3.4%; and several systems over time, 7.5%) were used.
The group had used these systems for a median of 7.5 (SD 10.0)
months. Analysis of caregivers’ socioeconomic status indicated
that the cohort was evenly distributed across a range of income
groups. The responding caregivers’ employment rate was 91.4%,
with 58.4% working full-time and 31.8% working part-time.
Analysis of the education level showed that 65.2% had an
academic or professional degree.
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aDIYAPS: Do-it-Yourself Artificial Pancreas Systems.
On an average, the cohort already had a baseline glycemic
control level below the target HbA1c recommended by the
International Society for Pediatric and Adolescent Diabetes
[11]. Nevertheless, a significant HbA1c improvement of –0.64
percentage points, from a mean HbA1c of 6.91% (SD 0.88%;
or 52.0 mmol/mol) to 6.27% (SD 0.67; or 45.0 mmol/mol) after
commencing DIYAPS was reported (P<.001; Figure 1). The
mean TIR increased from 64.2% (SD 15.94%) to 80.68% (SD
9.26; P<.001; Figure 2). Participants also reported a continuous
HbA1c improvement over time, starting from a mean HbA1c of
6.39% (SD 0.65%; or 46.3 mmol/mol) as their first result after
commencement, which equals an improvement of –0.52
percentage points compared to the baseline level, gradually
improving to a mean HbA1c of 6.26% (SD 0.69%; or 44.9
mmol/mol) as their second result and a mean HbA1c of 6.06%
(SD 0.66%; or 42.7 mmol/mol) as their third result, which equals
an improvement of –0.85 percentage points. Users of all
DIYAPS systems and all age groups showed similar results
(Table 2).
Among the relatively few respondents who indicated difficulties
with DIYAPS (n=29), the primary challenge was sourcing the
necessary devices and setting up the closed loop. In both cases,
successful solutions were primarily found online, although for
some, this was a time-consuming process.
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Figure 1. Mean last HbA1c levels of children and adolescents before (black) and after (white) the initiation of Do-it-Yourself Artificial Pancreas
Systems. HbA1c: hemoglobin A1c.
Figure 2. Mean time in range for sensor glucose levels of children and adolescents before (black) and after (white) the initiation of Do-it-Yourself
Artificial Pancreas Systems.
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Table 2. Clinical outcomes in children and adolescents before and after initiation of Do-it-Yourself Artificial Pancreas Systems.
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aDIYAPS: Do-it-Yourself Artificial Pancreas Systems.
bHbA1c: hemoglobin A1c.
Discussion
This survey is currently the largest study of DIYAPS users on
a global level and provides new evidence about real-world use
of these systems in children and adolescents. Improvement of
glycemic control was consistently reported across all pediatric
age groups, including adolescents and very young children.
Thus, the beneficial effects observed in adult users appear to
apply to the pediatric population with no age limitations. These
findings are in line with clinical trial results and improvements
seen in commercially developed closed-loop systems [5-9].
The occupational and educational level of the responding
caregivers was well above the population level; however, the
household income levels varied. This finding suggests that
DIYAPS may be financially accessible to a variety of
socioeconomic groups. Further investigations on the role of all
household caregivers’ socioeconomic status and barriers to
scaling up use of these systems would be of interest.
Although studies investigating DIYAPS consistently have
demonstrated significant improvements in a variety of clinical
and patient-reported outcomes, with no accompanying severe
adverse events, various stakeholders continue to view the use
of DIYAPS with skepticism. Ethical and legal questions have
been raised, especially for the vulnerable group of children and
adolescents. The off-label use of unregulated medical devices
as well as the role of the caregiver taking the decision
independently from doctors is the subject of intense debate [15].
Children are dependent on their caregivers’ technological and
medical knowledge and skills, both of which are prerequisites
of understanding, building, and maintaining a DIYAPS.
Moreover, a limited number of diabetes specialists are familiar
with DIYAPS and their in-built safety mechanisms. Knowledge
is also limited because research focusing on pediatric cohorts
have tended to lag behind the adult population. Studies such as
this one may therefore help alleviate concerns of health care
providers as they are increasingly confronted with caregivers
who have opted for DIYAPS for their child’s diabetes
management in their day-to-day clinical practice.
This study has several limitations. Outcomes were self-reported
by caregivers. Until recently, self-reported data have not been
commonly used in clinical research. However, a Norwegian
study previously found that self-reported outcomes showed
good concordance with data from patient registries reported by
health care professionals [16]. Continuous glucose monitoring
data were not directly captured in this survey. Therefore, time
in hypoglycemia was not assessed. Time spans between HbA1c
measurements and TIR as well as DIYAPS versions, settings,
and targets might differ individually. With a median DIYAPS
experience of 7.5 months, some participants were unable to
provide all three HbA1c measurements. With education level
and occupational status above the average population level and
previous baseline glycemic outcomes below the target, the
cohort or DIYAPS community may, in general, not be
representative of all families having children with diabetes. To
fully evaluate both the benefits and risks of DIYAPS, safety
and efficacy trials for all age groups are needed.
The growing #WeAreNotWaiting movement globally is
indicative of a paradigm shift whereby traditional, top-down
health care solutions are increasingly being complemented by
bottom-up and patient-led initiatives. This survey, novel in both
its sample size and international scope, provides new evidence
that DIYAPS can offer substantial improvements in clinical
outcomes for children and adolescents, even in a population
that already has achieved glycemic outcomes below the target.
However, more research is needed to examine the mechanisms
by which these results are achieved; lived experiences of
DIYAPS users; adverse events; and what can be learned from
this movement in order to accelerate the diffusion of APS
technology across the population.
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